No Data
Yakkang Biotech: Yakang Biotech 2024 Annual Performance Report Announcement
Yakkang Biotech 2024 Annual Results Express Announcement
YaoKang Bio (688046.SH): Net income for the year 2024 is 0.116 billion yuan, a decrease of 27.14% year-on-year.
On February 27, Gelonghui reported that Yaokang Biotechnology (688046.SH) announced its performance forecast for the year 2024. During the reporting period, the company achieved revenue of 686.7998 million yuan, an increase of 10.38% compared to the same period last year; it achieved a net income attributable to the parent company of 115.7887 million yuan, a decrease of 27.14% compared to the same period last year; it achieved a net income attributable to the parent company, deducting non-recurring gains and losses, of 81.9228 million yuan, a decrease of 23.57% compared to the same period last year.
Guosen: Focus on AI + Medical, high-quality innovation, and value symbols with stable performance.
Guosen remains bullish on companies with differentiated innovation capabilities and overseas potential.
An Intrinsic Calculation For GemPharmatech Co., Ltd. (SHSE:688046) Suggests It's 43% Undervalued
YaoKang Biological (688046.SH): There is currently no research on brain nerve signal acquisition, decoding, control, and feedback.
On January 17, Gelonghui reported that Yaokang Biotechnology (688046.SH) stated on its investor interaction platform that the company currently has no research in areas such as brain neural signal acquisition, decoding, control, and feedback. However, the company has a rich reserve of experimental animal models for neurological diseases and related pathway-targeted gene knockout mouse models. Additionally, the company can provide diagnostic testing, pathological testing, and behavioral testing services that simulate/compare with corresponding clinical patients, which can be offered to downstream customers for related research.
Investor Optimism Abounds GemPharmatech Co., Ltd. (SHSE:688046) But Growth Is Lacking
